Background:To determine whether initiating a glucagon-like peptide-1 receptor agonist(GLP-1 RA)within 3 months of type 2 diabetes(T2DM)diagnosis alters the subsequent risk of overall and site-specific cancer and wheth...Background:To determine whether initiating a glucagon-like peptide-1 receptor agonist(GLP-1 RA)within 3 months of type 2 diabetes(T2DM)diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index(BMI).Methods:This retrospective cohort study used electronic health records from the TriNetX U.S.research network.Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis.Following 1:1 propensity score matching,both the GLP-1 RA user and non-user groups included 183,264 patients.The study outcome was defined as a diagnosis of malignant neoplasms.Hazard ratios(HRs)for overall and site-specific cancer risk were estimated using Cox proportional hazards models.Kaplan–Meier analysis and stratified analysis by BMI were performed.Results:Early GLP-1 RA use demonstrated a modest but significant association with reduced overall cancer risk(HR 0.93;95%CI:0.90–0.96).Reduced risks were noted for cancers of the digestive(HR 0.81),respiratory(HR 0.66),and female genital(HR 0.87)systems.In stratified analysis,benefits were more pronounced in patients with BMI≥30,particularly for pancreatic and colorectal cancers.Conclusion:Early initiation of GLP-1 receptor agonists in patients with diagnosed T2DM was associated with a modest reduction in overall cancer risk,particularly among individuals with obesity.These findings highlight the dual metabolic and oncologic value of prompt GLP-1 RA therapy.展开更多
2025年8月30日,上海交通大学公共卫生学院王慧教授课题组在The Lancet子刊eClinicalMedicine上发表了题目为“Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarke...2025年8月30日,上海交通大学公共卫生学院王慧教授课题组在The Lancet子刊eClinicalMedicine上发表了题目为“Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity”的系统综述与meta分析。该研究系统检索并整合了全球范围内相关随机对照试验,最终纳入33项研究共12028名超重或肥胖成人受试者,以体质量变化主要结局指标,以体质量变化百分比、腰围、体成分、血压、血糖以及血脂相关指标为次要结局,采用随机效应模型全面评估了生活方式干预联合胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1RAs)在超重或肥胖人群中的疗效。该研究强调了药物与行为干预联合应用在肥胖管理中的附加价值,为推进个体化、综合性的体质量管理策略提供了重要科学依据。展开更多
基金financial support fromthe Chung Shan Medical University Hospital,Taiwan(CSH-2022-A-009).
文摘Background:To determine whether initiating a glucagon-like peptide-1 receptor agonist(GLP-1 RA)within 3 months of type 2 diabetes(T2DM)diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index(BMI).Methods:This retrospective cohort study used electronic health records from the TriNetX U.S.research network.Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis.Following 1:1 propensity score matching,both the GLP-1 RA user and non-user groups included 183,264 patients.The study outcome was defined as a diagnosis of malignant neoplasms.Hazard ratios(HRs)for overall and site-specific cancer risk were estimated using Cox proportional hazards models.Kaplan–Meier analysis and stratified analysis by BMI were performed.Results:Early GLP-1 RA use demonstrated a modest but significant association with reduced overall cancer risk(HR 0.93;95%CI:0.90–0.96).Reduced risks were noted for cancers of the digestive(HR 0.81),respiratory(HR 0.66),and female genital(HR 0.87)systems.In stratified analysis,benefits were more pronounced in patients with BMI≥30,particularly for pancreatic and colorectal cancers.Conclusion:Early initiation of GLP-1 receptor agonists in patients with diagnosed T2DM was associated with a modest reduction in overall cancer risk,particularly among individuals with obesity.These findings highlight the dual metabolic and oncologic value of prompt GLP-1 RA therapy.
文摘2025年8月30日,上海交通大学公共卫生学院王慧教授课题组在The Lancet子刊eClinicalMedicine上发表了题目为“Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity”的系统综述与meta分析。该研究系统检索并整合了全球范围内相关随机对照试验,最终纳入33项研究共12028名超重或肥胖成人受试者,以体质量变化主要结局指标,以体质量变化百分比、腰围、体成分、血压、血糖以及血脂相关指标为次要结局,采用随机效应模型全面评估了生活方式干预联合胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1RAs)在超重或肥胖人群中的疗效。该研究强调了药物与行为干预联合应用在肥胖管理中的附加价值,为推进个体化、综合性的体质量管理策略提供了重要科学依据。
